Amyotrophic Lateral Sclerosis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporati

Amyotrophic Lateral Sclerosis Pipeline constitutes 75+ key companies continuously working towards developing 80+ Amyotrophic Lateral Sclerosis treatment therapies, analyzes DelveInsight.

Amyotrophic Lateral Sclerosis Overview:

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative disorder affecting motor neurons. While no single cause has been identified, both genetic (familial) and non-genetic (sporadic) factors contribute to the disease. ALS typically affects both upper and lower motor neurons, often starting with weakness in the limbs and leading to progressive paralysis and death.

The exact cause of sporadic ALS remains unclear, with several potential mechanisms proposed, including abnormal RNA processing, SOD1 mutations leading to free radical damage, inflammation, and excessive glutamate. Familial ALS is more rare and often involves genetic mutations, such as C9ORF72 gene repeat expansions and SOD1 mutations. Both genetic forms are inherited in an autosomal dominant pattern, contributing to the disease's complex etiology.

Respiratory issues are a major concern in ALS patients due to weakening of the muscles involved in breathing. Noninvasive ventilation is often recommended for symptoms like difficulty breathing or low forced vital capacity (FVC). If necessary, invasive ventilation may be considered. Swallowing difficulties (dysphagia) are common and managed with diet changes, and enteral feeding via a G-tube may be needed to address weight loss.

Complications of ALS include respiratory decline, dysphagia, speech and muscle problems, malnutrition, spasms, fatigue, and issues with salivation and mucus production. Additionally, some medications used to manage ALS symptoms can cause side effects, such as gastrointestinal upset, liver issues, or headaches.

Request for a detailed insights report on Amyotrophic Lateral Sclerosis pipeline insights @ https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Amyotrophic Lateral Sclerosis Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Amyotrophic Lateral Sclerosis Therapeutics Market.

Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report

DelveInsight's Amyotrophic Lateral Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Amyotrophic Lateral Sclerosis treatment.
In November 2024, Ractigen Therapeutics announced that its siRNA therapy RAG-21, which targets ALS associated with FUS gene mutations, received Orphan Drug Designation from the FDA.
Key Amyotrophic Lateral Sclerosis companies such as Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, and others are evaluating new drugs for Amyotrophic Lateral Sclerosis to improve the treatment landscape.
Promising Amyotrophic Lateral Sclerosis pipeline therapies in various stages of development include MN-166, RNS60, VM202, QRL-201, and others.

Amyotrophic Lateral Sclerosis Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Amyotrophic Lateral Sclerosis Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Amyotrophic Lateral Sclerosis treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Amyotrophic Lateral Sclerosis market.

Download our free sample page report on Amyotrophic Lateral Sclerosis pipeline insights @ https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Amyotrophic Lateral Sclerosis Emerging Drugs

MN-166: MediciNova
RNS60: Revalesio
VM202: Helixmith
QRL-201: QurAlis Corporation

Amyotrophic Lateral Sclerosis Companies

There are over 75 key companies working on developing therapies for Amyotrophic Lateral Sclerosis. Among them, MediciNova has drug candidates for ALS in the most advanced stages, specifically Phase II/III.

DelveInsight's report covers around 80+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Amyotrophic Lateral Sclerosis Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Amyotrophic Lateral Sclerosis Therapies and Key Companies: Amyotrophic Lateral Sclerosis Clinical Trials and advancements @ https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Amyotrophic Lateral Sclerosis Pipeline Therapeutic Assessment
• Amyotrophic Lateral Sclerosis Assessment by Product Type
• Amyotrophic Lateral Sclerosis By Stage
• Amyotrophic Lateral Sclerosis Assessment by Route of Administration
• Amyotrophic Lateral Sclerosis Assessment by Molecule Type

Download Amyotrophic Lateral Sclerosis Sample report to know in detail about the Amyotrophic Lateral Sclerosis treatment market @ Amyotrophic Lateral Sclerosis Therapeutic Assessment @ https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Amyotrophic Lateral Sclerosis Current Treatment Patterns
4. Amyotrophic Lateral Sclerosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Amyotrophic Lateral Sclerosis Late-Stage Products (Phase-III)
7. Amyotrophic Lateral Sclerosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Amyotrophic Lateral Sclerosis Discontinued Products
13. Amyotrophic Lateral Sclerosis Product Profiles
14. Amyotrophic Lateral Sclerosis Key Companies
15. Amyotrophic Lateral Sclerosis Key Products
16. Dormant and Discontinued Products
17. Amyotrophic Lateral Sclerosis Unmet Needs
18. Amyotrophic Lateral Sclerosis Future Perspectives
19. Amyotrophic Lateral Sclerosis Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Amyotrophic Lateral Sclerosis Pipeline Reports Offerings: https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.